Colicins are bactericidal proteins that are produced by about 50% of Escherichia coli isolates from humans. Colicins usually act only on E. coli strains because of the elaborate uptake system required for entry into sensitive cells. Their uptake is initiated by binding to colicin-specific receptor proteins located in the outer membrane (5, 6) . After the colicins have bound to the receptor proteins, further translocation of the colicins is mediated by either the Ton or the Tol system. The Tol system consists of the proteins TolA, TolB, TolQ, and TolR (33) ; the Ton system consists of the proteins TonB, ExbB, and ExbD (4, 5, 21) . For the Ton-dependent colicins, it has been shown that the electrochemical potential of the cytoplasmic membrane drives their uptake across the outer membrane (2, 10) . Uptakedefective mutants with point mutations in tonB are suppressed by point mutations in receptors and in colicins, suggesting the interaction of TonB with these proteins (11) . This conclusion is supported by the location of the suppressor sites in a consensus sequence (TonB box) close to the N terminus of the TonBdependent receptors and colicins (1, 15, 20, 25) .
Recently, a new colicin, designated colicin 5, has been described (3) . Colicin 5 uptake is unusual because it requires the Ton system, although its cognate receptor Tsx is only known to function with the Tol system, as determined for the uptake of colicin K. An additional colicin, colicin 10, exhibited the same properties as colicin 5 (2a) . A molecular genetic study of the colicin 10 determinant has revealed a strong homology between colicin 10 and colicin E1 in the domains with similar functions (18) . Both colicins require the TolC protein for uptake (18) , and colicin E1 forms pores in the cytoplasmic membrane (8) , which can also be inferred for colicin 10 . The amino acid sequences in the regions proposed to determine binding of colicin 10 to the Tsx receptor and uptake via the Ton system are different from those proposed to determine binding of colicin E1 to the BtuB receptor and uptake via the Tol system (18) .
In this study, we investigated the colicin 5 determinant because it uses the same uptake system as colicin 10 and confers no cross-immunity to colicins 10 and E1, in contrast to the colicin 10 immunity protein, which cross-reacts with colicin E1. Since cross-immunity among colicins is unusual (in fact, closely related colicins can be differentiated by their specific immunities), it is of interest to unravel the similarities and differences among the immunity proteins and among the regions of the colicins that interact with the immunity proteins. By this means, one could expect to define the sites of the colicins and the immunity proteins responsible for their specific interactions. The understanding of the immunity to pore-forming colicins is still incomplete, since binding of these colicins to the immunity proteins has not been demonstrated. It is thought that pore-forming colicins are inactivated by the immunity proteins before they enter the cytoplasmic membrane or during pore formation. In this study, we identified the specific regions of interaction of the pore-forming colicin 5 and of the cognate immunity protein. According to the predicted transmembrane arrangement of the colicin and the immunity protein, the interacting sites are located at the inner side of the cytoplasmic membrane. This implies inactivation of the colicin at the very last moment before the cells are killed.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. Bacterial strains and plasmids used in this study are described in Table 1 . All strains were grown in a medium composed of 1% Bacto tryptone-0.5% yeast extract-0.5% NaCl (TY), pH 7, or on TY agar plates. When necessary, media were supplemented with kanamycin at 50 g/ml or chloramphenicol at 50 g/ml. The ampicillin resistance of strains carrying cfi-blaM fusion genes was tested on TY agar plates supplemented with increasing concentrations of ampicillin (5, 25, 50, 100, 200 , and 400 g/ml).
Recombinant DNA techniques. Plasmid DNA was isolated with ion-exchange columns from Qiagen (Hilden, Germany). Standard methods were used for restriction endonuclease analyses, ligation, and transformation of plasmid DNA (22) . Subclones of plasmid pHP20 were constructed with the vectors pBCSKϩ and pBCKSϩ (Stratagene, Heidelberg, Germany). Sequencing was performed by the dideoxy chain termination method (23) with an AutoRead sequencing kit (Pharmacia Biotech, Freiburg, Germany) and an ALF Automatic Sequenator (Pharmacia Biotech). Site-specific mutagenesis was performed by the PCR technique (12) . The nucleotide sequence of the primer employed for the insertion of the BfrI restriction site into the cfa gene is given as an example of the mismatch primers used for PCR (nucleotide replacement underlined): 5Ј-CTCGACTA GTGATCTTAAGCGACTTTG-3Ј. The sequences of the mutagenized frag-ments were verified by DNA sequencing. For constructing cfi-blaM gene fusions, blunt-ended restriction sites were introduced into the cfi gene. After amplification by the PCR technique, the cfi gene fragments were cloned into the pJBS636 vector, forming cfi-blaM gene fusions. pJBS636, a ␤-lactamase fusion vector, was derived from the pJBS633 vector (7); pJBS636 also carries the T7 promoter and the multiple cloning site of plasmid pT7-7 (9a).
Radiolabeling of proteins. cfi-blaM gene fusions were transcribed under the control of the gene 10 promoter of phage T7 by T7 RNA polymerase, which was chromosomally encoded in E. coli BL21 and was under the control of the lacI repressor. Cells (2 ml) in the exponential growth phase (optical density at 578 nm, 0.4) were collected by centrifugation and then resuspended in 1 ml of a medium containing 0.6% Na 2 HPO 4 , 0.3% KH 2 PO 4 , 0.1% NH 4 Cl, 0.05% NaCl, 1 mM MgSO 4 , 0.1 mM CaCl 2 , 1 mM sodium citrate, 0.4% glucose, 20 mg of thiamine per liter, and 0.01% methionine assay medium (Difco Laboratories, Detroit, Mich.). T7 RNA polymerase synthesis was induced by adding 1 mM isopropyl-␤-D-thiogalactopyranoside. After the culture was shaken for 60 min at 37ЊC, 20 l of rifamycin (20 mg/ml, in methanol) was added to inhibit the E. coli RNA polymerase and the culture was shaken for an additional 30 min. Cells were then labeled by adding 185 kBq of [ 35 S]methionine and incubating the culture for 15 min at room temperature. Cells were sedimented by centrifugation, resuspended in 40 l of sample buffer, and heated for 5 min at 100ЊC. Ten microliters was applied to a polyacrylamide gel (3% stacking gel, 15% running gel) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the presence of 0.1% SDS. The dried gel was autoradiographed with Kodak X-Omat S100 film.
Colicin activity assays. Colicin activity was tested by spotting 10-fold dilutions of colicin crude extracts onto plates, containing 20 ml of TY agar, which were then overlaid with 3 ml of low-melting-point TY agar in which 0.1 ml of an overnight culture of the indicator bacterium had been suspended (15) . Mutant strains were compared with their parent strains.
Purification of colicins 5 and 10. Colicins 5 and 10 were purified from E. coli W3110 cells harboring the natural plasmids pCol5 and pCol10, respectively; the recovery of active colicins from strains carrying natural plasmids was better than that from E. coli cells carrying cloned colicin genes. E. coli W3110 transformed with pCol5 or pCol10 was grown in TY medium to an optical density at 578 nm of 1 and subsequently treated with mitomycin C (400 ng/ml) for 3 h. Cells were collected by centrifugation, and the proteins remaining in the supernatant were precipitated with 50% (NH 4 ) 2 SO 4 . The precipitate was dissolved in 100 mM sodium phosphate (pH 7.2) and desalted with a PD10 gel filtration column (Pharmacia) equilibrated with 100 mM sodium phosphate buffer (pH 7.2). The eluate was centrifuged (10,000 ϫ g, 10 min). The clear supernatant fluid was then applied to a Resource Q anion-exchange column (Pharmacia) and chromatographed by fast-performance liquid chromatography (Pharmacia) with a linear gradient of NaCl from 0 to 1 M in the sodium phosphate buffer. Each colicin appeared as a single peak that was eluted at about 0.25 M NaCl. The purity of colicins 5 and 10 was assessed by SDS-PAGE (13) . To estimate the molecular masses of the colicins, their electrophoretic mobilities were compared with those of standard proteins by using a 10-kDa protein ladder (Gibco BRL, Eggenstein, Germany).
Computer analysis. Nucleotide and amino acid sequences were analyzed with the PC/GENE software package, with the programs CLUSTAL for performing multiple alignments, PALIGN for searching for homologies between proteins, and NALIGN for comparing nucleotide sequences.
Nucleotide sequence accession number. The nucleotide sequence reported in this study was deposited in the EMBL data bank under the accession no. X87835.
RESULTS
Cloning of the colicin 5 genes. The natural plasmid pCol5 ( Fig. 1 ) was digested with EcoRI-HindII, and the restriction fragments were cloned into plasmid pBCKSϩ. Transformants of E. coli 5K were screened for colicin activity with colicin 5-sensitive untransformed E. coli 5K. A 4.7-kb fragment conferred colicin activity; a 2,166-bp BspHI-XhoII subfragment was completely sequenced (both strands). The nucleotide sequence contained three open reading frames, designated cfa (colicin 5 activity), cfi (colicin 5 immunity), and cfl (colicin 5 lysis) (Fig. 2 ). cfa and cfl had the same transcription polarity, and cfi had the opposite polarity (Fig. 1) , an arrangement typical for the genes of all pore-forming colicins. cfa, cfi, and cfl encode proteins of 490 (M r , 53,137), 96 (M r , 11,498), and 43 (M r , 4,556) amino acid residues, respectively. The electrophoretic mobility of purified Cfa in an SDS-polyacrylamide gel corresponded to an M r of 57,000 (Fig. 3, lane 2) , which is indistinguishable from the position of purified colicin 10 (Cta) (Fig. 3, lane 3) .
Homology between colicins 5 and 10. Colicins 5 and 10 require the same proteins for import into sensitive cells ( Table  2) . Comparison of the Cfa protein (colicin 5) with the Cta protein (colicin 10) revealed a 93.7% overall identity (Fig. 4) . Since the proteins have the same length, no sequence gaps had to be introduced to improve homology. The domains proposed to determine the TonB and TolC interaction (18) are com- (18) are 99.1% identical in the two colicins. In contrast, the C-terminal pore-forming domains display only 83.7% identity. In particular, a region comprising 38 residues (residues 387 to 424) contains different amino acids at 22 sites (partly underlined in Fig. 4) . Since the C-terminal region of colicins usually interacts with the respective immunity proteins (6), the different sequences might determine the various immunity specificities (Table 2 ). This region of 38 amino acid residues is displayed in Fig. 5 , in which the corresponding region of colicin E1 is included for comparison because of the cross-reaction of Cti with colicin E1. (However, the colicin E1 immunity protein does not crossreact with Cta [18] ).
Determination of the region in colicin 5 that determines the immunity specificity. The sequence WAKHLE (D) in colicins 10 and E1 (Fig. 5 ) reads LSKNLT in colicin 5. To see whether these sequences determine the cross-reaction of Cti with colicins 10 and E1 and the lack of cross-reaction with colicin 5, LSKNLT of colicin 5 was converted to WAKHLE by PCR. Modified colicin 5 was fully active but retained specificity for Cfi (Table 2) . Therefore, the region downstream of WAKHLE or LSKNLT was exchanged between colicins 5 and 10, taking advantage of a BfrI restriction site in cta; a BfrI site was introduced into cfa by PCR (after lysine number 404 [marked by an . The cell extract containing the colicin 5-colicin 10 hybrid protein was somewhat less active than the extract containing colicin 10-colicin 5, which was as active as colicin 5 (Table 2 ). Cti conferred immunity to colicin 5-colicin 10, and Cfi conferred immunity to colicin 10-colicin 5 (Table  2) , which localized the immunity region of both colicins to the segment downstream of residue 404. This confines the immunity-specifying determinants of both colicins to the region in which they differ from residue 405 to residue 424. Determination of the regions in the immunity proteins that recognize colicins 5 and 10. Cfi and Cti exhibit the greatest identity (65.6%) among the immunity proteins of pore-forming colicins (Fig. 6 ). Cfi and Cti contain three nonhomologous regions that are potential candidates for the specific interaction with Cfa and Cta, respectively. To determine which of the nonhomologous regions specifies recognition of the cognate colicin, both immunity genes were cleaved by NspI, which cuts at the same position in cfi and cti. Exchange of the fragments, which allowed the exchange of two of the three nonhomologous regions, resulted in the hybrid proteins Cfi-Cti and CtiCfi, with fusion sites after histidine 40 (marked by an arrow in Fig. 6 ). E. coli 5K transformed with pHP41 cfi-cti was immune to added colicin 10, and transformants carrying pHP42 cti-cfi were immune to colicin 5 ( Table 3 ), showing that one or both of the nonhomologous regions determine the respective immunity specificities against colicins 5 and 10.
The immunity protein inactivates the colicin at the inner side of the cytoplasmic membrane. The hydropathy profile of the Cfi immunity protein, like that of the Cti immunity protein (18) , shows three hydrophobic segments that are predicted to form three ␣-helices across the cytoplasmic membrane (Fig. 7) . To support this model, hybrid proteins between the colicin 5 immunity protein and ␤-lactamase (Bla) were constructed. Only fusions at sites located in the periplasmic space should allow cells to grow as single colonies on nutrient agar plates supplemented with 5 g of ampicillin per ml (7) . The Cfi-Bla hybrid in the N-terminal periplasmic loop (residue 27 of Cfi in L1 of Fig. 7 ) conferred resistance to 100 g of ampicillin per ml, whereas cells expressing the Cfi-Bla hybrid in the cytoplasmic loop (residue 63 in L2 of Fig. 7 ) formed no colonies on plates containing 5 g of ampicillin per ml. Cells expressing Cfi to which Bla was fused at the second-to-last amino acid (residue 95), predicted to be located in the periplasm, unexpectedly did not form colonies on plates containing 5 g of ampi- http://jb.asm.org/ cillin per ml. The cells lysed, and the released ␤-lactamase protected nearby cells so that growth zones with a high density of cells appeared on plates. However, these growth zones did not appear on plates containing the 200 g of ampicillin routinely used to identify in-frame ␤-lactamase hybrid proteins with cytoplasmic fusion sites (7); the zones appeared with cells that expressed the Cfi63-Bla hybrid in the cytoplasmic loop.
Cells expressing Cfi95-Bla grew in zones at a high density on plates containing 50 g of ampicillin per ml and grew less well on plates containing 100 g of ampicillin per ml. Apparently, Cfi95-Bla conferred a lower level of ampicillin resistance than did Cfi63-Bla, although sequencing of the cfi95-blaM fusion site confirmed the expected in-frame fusion.
To examine proteolytic degradation, Cfi95-Bla was expressed in E. coli KS474 degP, which lacks the periplasmic DegP protease (29) , which has been shown to cleave abnormal periplasmic proteins (28) . KS474 transformed with plasmid pHP46 (cfi95-blaM) formed colonies on plates containing 50 g of ampicillin per ml; no colonies of KS474 cells expressing Cfi63-Bla with a cytoplasmic fusion site formed on such plates. These data confirmed the hypotheses that active Cfi95-Bla was formed and that single colonies could grow in the presence of ampicillin, which indicates a periplasmic location of the fusion site.
To examine the degradation of Cfi95-Bla in degP ϩ cells, cfi95-blaM, cfi63-blaM, and cfi27-blaM were cloned downstream of the phage T7 promoter and transcribed by the T7 RNA polymerase in E. coli BL21. [ 35 S]methionine-labeled Cfi27-Bla, Cfi63-Bla, and Cfi95-Bla (Fig. 8, lanes 3 to 5, respectively) were present on the autoradiograph after SDS-PAGE. No evidence for inhibition of Cfi95-Bla synthesis or degradation was found. In fact, the Cfi95-Bla band gave a stronger signal than did the bands of the other hybrid proteins, and pulse-chase labeling did not reveal Cfi95-Bla degradation (data not shown). The increase in ampicillin resistance was related to the degP mutant phenotype since the parent, E. coli MC4100 degP ϩ pHP46 cfi95-blaM, and the other degP ϩ strain tested, E. coli BL21 pHP46, were as sensitive to ampicillin as E. coli 5K pHP46 was.
Cfi27-Bla and Cfi63-Bla conferred no immunity to Cfa on E. coli 5K transformants (Table 3 ). In contrast, E. coli 5K expressing Cfi95-Bla was as immune to added Cfa as was E. coli 5K expressing Cfi (Table 3) .
DISCUSSION
The amino acid sequences of Cfa and Cfi are most homologous to the respective amino acid sequences of the activity, immunity, and lysis proteins of colicins 10, E1, Ia, Ib, and K (14, 18, 19, 32, 35) . Therefore, data on pore formation of colicins E1 (8) The topography of the colicin E1 immunity protein is supported by TnphoA and lacZ fusions and by site-directed substitutions of charged residues for nonpolar residues in the proposed membrane-spanning regions (27) . The colicin E1 immunity model predicts three transmembrane helices, the N-terminal end localized in the cytoplasm, and the C-terminal end localized in the periplasm. In agreement with the predicted membrane topology of Cfi, the ␤-lactamase activities of the Cfi27-Bla and Cfi63-Bla hybrid proteins localized L1 to the periplasm and L2 to the cytoplasm (Fig. 7) . Although the level of ␤-lactamase activity of Cfi95-Bla was lower than that of Cfi27-Bla, growth of single colonies in the degP strain demonstrated a periplasmic fusion site, implying that residue 95 is in the periplasm as the model proposes. However, only the degP strain containing cfi95-blaM formed single colonies on plates containing ampicillin, despite the lack of Cfi95-Bla degradation in degP ϩ cells. Since sequencing of the cfi95-blaM fusion site and SDS-PAGE of radioactively labeled Cfi95-Bla demonstrated the correctness of the fusion, we assume that the immunity protein prevented the folding of ␤-lactamase into its native conformation. A small proportion was active and was partially degraded by DegP so that the level of resistance was not high enough to allow growth of single colonies. In the degP mutant, this small proportion remained active and conferred resistance to ampicillin.
The model assigns the amino acids responsible for the specific reaction with colicin 5 (shaded residues in Fig. 7) to the cytoplasm and to the inner side of the cytoplasmic membrane. This implies that the immunity protein does not inactivate the colicin in the periplasmic space and thus does not prevent it from entering the cytoplasmic membrane. This conclusion is supported by the location of the interacting region in colicin 5. The specificity-determining region was localized to residues 405 to 424. The homologous region in colicin Ia is located immediately C terminal to the ''swinging gate,'' the segment, comprising at least residues 511 to 541, that is translocated across a planar lipid bilayer upon application of a transmembrane voltage (26) . Translocation of this segment is associated with opening of the channel. In colicin A, the region equivalent to the Cfi specificity region is contained in helix 6 of the X-ray structure obtained with a crystallized C-terminal fragment (17) . This helix is proposed to be inserted into the cytoplasmic membrane upon opening of the channel (17) . Since these topographic data probably also apply for colicin 5, the immunity protein interacts with regions on the colicin that are located in the inner leaflet of the cytoplasmic membrane. This proposal also implies that helix 6 is translocated farther into the cytoplasmic membrane than has been previously proposed (26) . However, the membrane topology of pore-forming colicins of the colicin 5 type may differ in detail from those of the colicin A type. It was shown that the immunity proteins of colicins A (9) and E1 (36) interact with the transmembrane helices of the related colicins, from which it was inferred that they bind to the colicins in the open state. We favor the idea that the immunity proteins inactivate the pore-forming colicins when the helices are inserted into the cytoplasmic membrane shortly before the channels are opened.
